ClC-3/SGK1 regulatory axis enhances the olaparib-induced antitumor effect in human stomach adenocarcinoma

Currently, only a few available targeted drugs are considered to be effective in stomach adenocarcinoma (STAD) treatment. The PARP inhibitor olaparib is a molecularly targeted drug that continues to be investigated in BRCA-mutated tumors. However, in tumors without BRCA gene mutations, particularly...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Zhuoyu, Wang, Liping, Yao, Xiaohan, Long, Qian, Lee, Kaping, Li, Jieyao, Yue, Dongli, Yang, Shuangning, Liu, Yanfen, Li, Na, Li, Yixin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583252/
https://www.ncbi.nlm.nih.gov/pubmed/33093458
http://dx.doi.org/10.1038/s41419-020-03107-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7583252/
https://www.ncbi.nlm.nih.gov/pubmed/33093458
http://dx.doi.org/10.1038/s41419-020-03107-3

Ejemplares similares